The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we...
Main Authors: | Sonia Tejedor Vaquero, Leire de Campos-Mata, José María Ramada, Pilar Díaz, Juan Navarro-Barriuso, Clara Ribas-Llaurado, Natalia Rodrigo Melero, Carlo Carolis, Andrea Cerutti, Ramon Gimeno, Giuliana Magri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.737083/full |
Similar Items
-
COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing
by: Santiago Grau, et al.
Published: (2022-04-01) -
PECULIARITIES OF SPECIFIC HUMORAL MESLES IMMUNE RESPONSE
by: A. P. Toptygina, et al.
Published: (2014-07-01) -
Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
by: Matthias Becker, et al.
Published: (2022-10-01) -
IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study
by: Sergio Gil-Manso, et al.
Published: (2022-11-01) -
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
by: Frances Priddy, et al.
Published: (2024-12-01)